Nootropic effects of LSD: Behavioral, molecular and computational evidence

Exp Neurol. 2022 Oct:356:114148. doi: 10.1016/j.expneurol.2022.114148. Epub 2022 Jun 19.

Abstract

The therapeutic use of classical psychedelic substances such as d-lysergic acid diethylamide (LSD) surged in recent years. Studies in rodents suggest that these effects are produced by increased neural plasticity, including stimulation of the mTOR pathway, a key regulator of metabolism, plasticity, and aging. Could psychedelic-induced neural plasticity be harnessed to enhance cognition? Here we show that LSD treatment enhanced performance in a novel object recognition task in rats, and in a visuo-spatial memory task in humans. A proteomic analysis of human brain organoids showed that LSD affected metabolic pathways associated with neural plasticity, including mTOR. To gain insight into the relation of neural plasticity, aging and LSD-induced cognitive gains, we emulated the experiments in rats and humans with a neural network model of a cortico-hippocampal circuit. Using the baseline strength of plasticity as a proxy for age and assuming an increase in plasticity strength related to LSD dose, the simulations provided a good fit for the experimental data. Altogether, the results suggest that LSD has nootropic effects.

Keywords: Cognition; Computational model; Human brain organoids; LSD; Memory; Neuroplasticity; Psychedelic.

MeSH terms

  • Animals
  • Hallucinogens* / toxicity
  • Humans
  • Lysergic Acid Diethylamide / pharmacology
  • Nootropic Agents*
  • Proteomics
  • Rats
  • TOR Serine-Threonine Kinases

Substances

  • Hallucinogens
  • Nootropic Agents
  • Lysergic Acid Diethylamide
  • TOR Serine-Threonine Kinases

Associated data

  • Dryad/10.5061/dryad.hmgqnk9hb
  • Dryad/10.5061/dryad.k98sf7m6f
  • Dryad/10.5061/dryad.dncjsxm0g
  • Dryad/10.5061/dryad.d2547d838